)
Digital health company Vitura Health (ASX: VIT) says its Doctors on Demand telehealth business has surpassed one million consultations since the start of FY2024 and reached sustained EBITDA profitability, roughly two and a half years after acquiring the platform for $25 million.
The milestone caps a period of rapid growth for the telehealth unit, which has lifted its Q1-Q3 revenue from $14.1 million in FY2024 to $21.6 million in FY2026 - a 54 per cent increase over two years.
Consultations across the same nine-month windows rose from 210,518 to 311,152, while the daily consultation record climbed from 1,039 to 1,539.
The news follows Vitura's acquisition of Doctors on Demand in October 2023 for $18.75 million in cash and $6.25 million in shares, a deal the company's then-CEO Rodney Cocks described as a "significant milestone" and "game changer" for the group's diversification beyond medicinal cannabis.
At the time of acquisition, Doctors on Demand had about 200 doctors on its platform serving both consumer and corporate clients.
That number has since grown to more than 320, with the business expanding its after-hours and B2B telehealth offerings.
“When Vitura completed the acquisition of Doctors on Demand (DoD) in October 2023, the expectation was that it would be cash flow positive at completion with the aim to produce profitability soon after," says Vitura's chief revenue officer Ryan Tattle.
"We have achieved this and gone beyond, with DoD delivering positive operating cash flow and EBITDA during the first three quarters of FY2026.
"This is a meaningful outcome for both DoD and Vitura and reflects the discipline and capability of the team that has driven these record results.”
Tattle says Doctors on Demand's gross margin profile is "relatively stable and predictable", making the business an "increasingly important contributor to Vitura’s overall revenue and profit diversification".
"We have a mix of B2C and B2B patients, including consultations driven directly by private health insurers to Doctors on Demand which can also provide further sustainability,” he says.
Vitura sas the unit's EBITDA margin improved from negative 3 per cent in FY2024 to positive 5 per cent in FY2026, driven partly by a 4 per cent reduction in operating expenditure that yielded a 14 per cent efficiency improvement.
The company notes all FY2026 figures remain unaudited, with only half-year results to December 2025 formally audited to date.
The telehealth division has become an increasingly important contributor as Vitura's core medicinal cannabis business faces pricing compression.
The group's half-year results to December 2025 showed total revenue of $67.9 million, up 8.3 per cent on the prior corresponding period, but normalised EBITDA fell to $1.9 million from $4.6 million as margin pressure weighed on the broader business.
Within that half, Doctors on Demand delivered 21 per cent revenue growth and 15 per cent consultation growth compared with the prior corresponding period, with after-hours consultations up 32 per cent.
The platform operates a hybrid model serving individual patients through its consumer-facing telehealth service while also providing corporate telehealth solutions to employers.
Vitura says it expects Doctors on Demand to continue its growth trajectory into FY27, although it has not provided specific revenue or earnings guidance for the unit.
)
